FDA approves Takeda/Protagonist cancer drug Mimrylo as White House readies new drug pricing deals, BioNTech ends colon vaccine trial

The U.S. Food and Drug Administration gave approval to a weekly injection called Mimrylo, developed by Takeda and partner Protagonist Therapeutics, for treatment of a slow‑growing cancer. The agency’s decision clears the way for the drug to be marketed in the United States.

At the same time, the White House is expected to announce a set of drug‑pricing agreements that include major manufacturers such as Bayer, Takeda and CSL Behring. The deals aim to secure pricing concessions from the companies in exchange for broader salary relief, though the exact impact on drug costs remains unclear.

Separately, BioNTech announced the termination of its Phase 2 trial of a colon‑cancer vaccine, ending development of that candidate after the study was halted.